Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Blue Chip Shares
Analysts say these world-class ASX 200 blue-chip shares are buys
Healthcare Shares
Buy and hold this ASX 200 share which is a long term market leader: broker
Healthcare Shares
'Wave of innovation': Why ASX 200 healthcare shares are poised for new growth
Healthcare Shares
Cochlear share price goes green as guidance strikes a chord
Blue Chip Shares
2 strong ASX 200 blue chip shares to build a portfolio around
Share Market News
3 high-quality ASX 200 blue chip shares to buy this month
Investing Strategies
4 ASX 200 stocks that could cash in from a low Australian dollar
Blue Chip Shares
Here's why Goldman Sachs is bullish on these leading ASX 200 shares
Share Market News
5 things to watch on the ASX 200 on Monday
Share Market News
5 ASX 200 shares trading ex-dividend next week
Investing Strategies
'Strong leaders': Buy 2 ASX 200 stocks with quality earnings
Dividend Investing
Show us the money! The ASX shares delivering the best dividend upgrades this earnings season
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.